Narcolepsy

FDA Grants Fast Track Designation to Investigational Narcolepsy Treatment

The oral orexin 2 receptor agonist currently in phase 1b development for patients with narcolepsy.

Narcolepsy

Alkermes Granted Orphan Drug Designations for Alixorexton in US, Europe

The investigational oral orexin 2 receptor agonist received designations from the FDA for idiopathic hypersomnia and the European Commission for narcolepsy.

Narcolepsy

‘Conclusive Evidence That Narcolepsy Type 1 Is a Result of the Body’s Own Immune System’

Samples from deceased brain donors reveal specific T-cells that can target orexin/hypocretin-expressing cells.

Lilly to Acquire Centessa Pharmaceuticals to Advance Treatments for Sleep-Wake Disorders

Mar 31, 2026 | Emerging Compounds, Narcolepsy

The acquisition centers on Centessa’s pipeline of orexin receptor 2 agonists, including lead candidate cleminorexton, targeted for narcolepsy and idiopathic hypersomnia.

Alkermes Completes Acquisition of Avadel Pharmaceuticals, Adding LUMRYZ to Portfolio

Feb 13, 2026 | Narcolepsy, Prescription Drugs

The acquisition accelerates Alkermes’ entry into the sleep medicine market and incorporates the FDA-approved extended-release sodium oxybate treatment for narcolepsy.

Alkermes Increases Offer to Acquire Avadel

Nov 19, 2025 | Narcolepsy, Prescription Drugs

The increased offer values Avadel at up to approximately $2.37 billion.

The Overlooked Narcolepsy Symptom

Nov 12, 2025 | Narcolepsy

A man in his 40s sat in front of clinical psychologist Christopher Wendel, PhD, DBSM, one early afternoon on the grey couch where Wendel sees all his behavioral sleep therapy clients. “What brings you in?” Wendel asked.

Narcolepsy Patients Show Enhanced Brain Waste Clearance Through Compensatory Vasomotor Activity

Sep 24, 2025 | Narcolepsy

New research reveals how orexin deficiency may paradoxically improve glymphatic function when NT1 patients are awake.

The Once-Nightly, Salt-Free, Artificial Sweetener-Free Oxybate in the Works for Narcolepsy, IH

Sep 4, 2025 | Emerging Compounds, Narcolepsy

Avadel Pharmaceuticals has licensed valiloxybate from XWPharma Ltd.

Alkermes Orexin Receptor Agonist Shows Broad Benefits in Phase 2 Narcolepsy Study

Jul 21, 2025 | Emerging Compounds, Narcolepsy

Alkermes today released topline results from the randomized double-blind treatment period of the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1.

First Orexin Agonist in Phase 3 Trials for Narcolepsy

May 16, 2025 | Emerging Compounds, Narcolepsy

A phase 3 readout is anticipated later this year.

How Narcolepsy Gets Lost in Translation

Apr 4, 2025 | Narcolepsy

And what physicians can do by realizing that the words people use to describe their symptoms may not match the disorder’s medical description.

Harmony Biosciences Highlights 2025 Catalysts in Sleep/Wake Franchise

Feb 27, 2025 | Narcolepsy, Pharmaceuticals

Harmony Biosciences provides updates on WAKIX, pitolisant HD, pitolisant GR, and an orexin-2 receptor agonist.

Patient Facebook Group and Subreddit Reveal Burdens of Twice-Nightly Narcolepsy Therapy

Dec 11, 2024 | Narcolepsy

Results from a social media analysis and survey of people with narcolepsy uncover challenges with twice-nightly oxybate therapy.

Survey Reveals Power of Social Connections for Narcolepsy and IH Patients

Nov 22, 2024 | Idiopathic Hypersomnia, Narcolepsy

A global survey reveals that peer connections significantly improve support and adjustment for individuals with narcolepsy and idiopathic hypersomnia.

Avadel’s Narcolepsy Treatment Lumryz Brings in $50 Million in Q3

Nov 13, 2024 | Narcolepsy

During the quarter, Lumryz saw increased patient uptake, expanded to pediatric use, and secured a legal victory affirming its clinical superiority, as the company continues its phase 3 trial in idiopathic hypersomnia.